Aarti Pharmalabs reports 23.67% growth in PAT, but PBT and Net Sales decline in Q3 2024
Aarti Pharmalabs, a midcap pharmaceutical company, has reported a 23.67% year-on-year growth in Profit After Tax for the nine months ending September 2024. However, the Profit Before Tax and Net Sales for the quarter have shown a decline, raising concerns for investors. Non Operating Income has increased, but may not be sustainable.
Aarti Pharmalabs, a midcap pharmaceutical company, recently declared its financial results for the quarter ending September 2024. The company's stock has been given a 'Hold' call by MarketsMOJO.
According to the financials, Aarti Pharma's Profit After Tax (PAT) for the nine months ending September 2024 has shown a growth of 23.67% year on year, reaching Rs 175.32 crore. This indicates a positive trend in the company's profitability in the near term.
However, the Profit Before Tax less Other Income (PBT) for the quarter has fallen by -11.3% compared to the average PBT of the previous four quarters. This could be a cause for concern for investors as the near term trend for PBT is very negative.
Similarly, the company's Net Sales for the quarter have also shown a decline of -6.0% compared to the average Net Sales of the previous four quarters. This could be due to various factors such as market conditions or competition.
On a positive note, Aarti Pharma's Non Operating Income for the quarter has increased to Rs 4.48 crore, the highest in the last five quarters. However, it is important to note that this income may not be sustainable as it is from non-business activities.
Overall, Aarti Pharmalabs has shown a mixed performance in the quarter ending September 2024. Investors are advised to hold their positions and monitor the company's future financial results closely.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
Our weekly and monthly stock recommendations are here
Loading...
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
Most Read
